{"id":"NCT02141854","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","officialTitle":"A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2014-05-20","resultsPosted":"2017-04-12","lastUpdate":"2021-11-09"},"enrollment":882,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"FS MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid","salmeterol xinafoate","β2 adrenoceptor agonist"]},{"type":"DRUG","name":"Fp MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid"]},{"type":"DRUG","name":"Placebo MDPI","otherNames":["inert powder"]},{"type":"DRUG","name":"Albuterol/salmeterol HFA MDI","otherNames":["short-acting β2-adrenergic agonists"]}],"arms":[{"label":"FS MDPI 200 / 12.5 mcg","type":"EXPERIMENTAL"},{"label":"FS MDPI 100 / 12.5 mcg","type":"EXPERIMENTAL"},{"label":"Fp MDPI 200 mcg","type":"EXPERIMENTAL"},{"label":"Fp MDPI 100 mcg","type":"EXPERIMENTAL"},{"label":"Placebo MDPI","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.","primaryOutcome":{"measure":"Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12","timeFrame":"Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours","effectByArm":[{"arm":"FS MDPI 200 / 12.5 mcg","deltaMin":0.446,"sd":0.0463},{"arm":"FS MDPI 100 / 12.5 mcg","deltaMin":0.442,"sd":0.0496},{"arm":"Fp MDPI 200 mcg","deltaMin":0.267,"sd":0.0466},{"arm":"Fp MDPI 100 mcg","deltaMin":0.26,"sd":0.0463},{"arm":"Placebo MDPI","deltaMin":0.121,"sd":0.0472}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0009"},{"comp":"OG001 vs OG003","p":"0.0010"},{"comp":"OG000 vs OG004","p":"0.0000"},{"comp":"OG001 vs OG004","p":"0.0000"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":154,"countries":["United States","Canada","Czechia","Hungary","Poland","Russia","South Africa","Thailand","Ukraine"]},"refs":{"pmids":["28639542","27216137"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":143},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache"]}}